Navigation Links
VIVUS Reports First Quarter 2011 Financial Results
Date:5/2/2011

in the offspring of women who were exposed to topiramate during pregnancy. We have reached agreement, subject to the finalization of the written protocol, with the FDA on the retrospective observational study objectives and design, primary endpoints, and eligibility criteria. The co-primary endpoints will be the relative risk of major congenital malformations and oral cleft in the offspring of women exposed to topiramate during pregnancy as compared to a control group that was not exposed to topiramate. The retrospective observational study, will be called FORTRESS, for Fetal Outcome Retrospective TopiRamate ExpoSure Study. In addition, we discussed with the FDA a potential resubmission of the QNEXA NDA for a limited indication, which would include only men and women of non-child bearing potential. Agreement on the content of such a submission has also been reached, should we choose to pursue a limited indication. The final indication and timing of the resubmission will be dependent upon the results of the retrospective observational study. Our goal is to resubmit the QNEXA NDA in the fourth quarter of 2011. We have confirmed with the FDA that any resubmission will be considered a Class 2 resubmission with a 6-month review goal. The FDA has also indicated that a resubmission would likely be discussed at a second advisory committee meeting.  

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VIVUS to Present at Four Upcoming Investor Conferences in May
2. VIVUS to Present at the 10th Annual Needham Healthcare Conference
3. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
4. VIVUS to Present at Four Upcoming Investor Conferences
5. VIVUS to Present at Two Upcoming Investor Conferences
6. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
7. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
8. VIVUS to Present at Four Upcoming Healthcare Conferences
9. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
10. VIVUS to Present at the Needham and Company Life Sciences Conference
11. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, Inc. ... on gynecologic disease, announced today that the Company ... including Oracle Investment Management, Jack W. Schuler ... Total proceeds were $10.5 million, before offering expenses.  ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application and ... manufacturing process, and product cost structure. Production is ... also covers upstream raw materials, equipment, downstream client ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... technology is often touted as a way to improve supply ... is bringing other, perhaps more important benefits: safety and security. ... and there are tremendous applications in health care a ... Reik Read, an analyst with Robert W. Baird and ...
... its surface, radio frequency identification technology may seem simple: ... with an antenna enabling the transfer of data via ... antenna is where things can get complicated and challenging. ... price of transponders or tags down to the often-mentioned ...
... Wireless Facilities, Inc. , a global leader in the ... networks and security systems, announced today that it has ... for the City of Madison, Wisconsin's proposed municipal Wi-Fi ... in coordination with Madison Gas & Electric, WFI will ...
Cached Biology Technology:RFID can be a matter of life and death in the medical world 2RFID can be a matter of life and death in the medical world 3RFID can be a matter of life and death in the medical world 4RFID can be a matter of life and death in the medical world 5Making RFID mainstream 2Making RFID mainstream 3Making RFID mainstream 4
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... crops such as switchgrass and Miscanthus has focused ... into fuels. But many steps lead from the farm to ... of this new industry. A new computer model developed at ... The model can run millions of simulations, optimizing operations to ...
... Ind. - Researchers have created new "microtweezers" capable of ... make advanced sensors, and grab and position live stem ... used to assemble structures in microelectromechanical systems, or MEMS, ... currently are being used in commercial products. A wider ...
... , This release is available in German ... now be produced inexpensively and in large quantities. This means ... 225 million malaria patients in developing countries at an affordable ... Interfaces in Potsdam and the Freie Universitt Berlin have developed ...
Cached Biology News:From field to biorefinery: Computer model optimizes biofuel operations 2From field to biorefinery: Computer model optimizes biofuel operations 3New microtweezers may build tiny 'MEMS' structures 2New microtweezers may build tiny 'MEMS' structures 3Anti-malaria drug synthesized with the help of oxygen and light 2Anti-malaria drug synthesized with the help of oxygen and light 3
Agarose II (Low Melt)...
...
... Buffer I can be used in intracellular ... permeabilize cells and to serve as an ... saponin-mediated cell permeabilization is a reversible process, ... in the presence of saponin during intracellular ...
... antibody raised against a partial ... Immunogen: PPP4C (NP_002711, 218 ... recombinant protein with GST tag. ... NM_002720 ...
Biology Products: